Is phosphoproteomics ready for clinical research?

Clinica Chimica Acta

Volumn 420, Issue , 2013, Pages 23-27

  Iliuk, Anton B ^a,b   Tao, W Andy ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Mass spectrometry; Phosphoproteomics; Signaling

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHOPEPTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; GENOMICS; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PHOSPHOPROTEOMICS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION;

BIOMEDICAL RESEARCH; HUMANS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEOMICS;

EID: 84877618069     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.10.063     Document Type: Article

References (48)

1. Hood L., Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol 2012, 29:613.
2. Buchdunger E., Zimmermann J., Mett H., et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A 1995, 92:2558.
3. Druker B.J., Lydon N.B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000, 105:3.
4. Mauro M.J., Druker B.J. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001, 6:233.
5. Sherbenou D.W., Druker B.J. Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007, 117:2067.
6. Knight K.A., Shokat K.M. Features of selective kinase inhibitors. Chem Biol 2005, 12:621.
7. Juan W.C., Ong S.T. The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia. Prog Mol Biol Transl Sci 2012, 106:107.
8. Hu Y., Liu Y., Pelletier S., et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004, 36:453.
9. Hu Y., Swerdlow S., Duffy T.M., Weinmann R., Lee F.Y., Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 2006, 103:16870.
10. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500.
11. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399.
12. Rubin B.P., Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest 2006, 86:981.
13. Carayol N., Vakana E., Sassano A., et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 2010, 107:12469.
14. Chu S., Holtz S., Gupta M., Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004, 103:3167.
15. Chan D.A., Giaccia A.J. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011, 10:351.
16. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, 5:689.
17. Haura E.B. From modules to medicine: how modular domains and their associated networks can enable personalized medicine. FEBS Lett 2012, 586:2580.
18. Riedel R.F. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?. Semin Oncol 2011, 38(Suppl. 3):S30.
19. Mischel P.S., Shai R., Shi T., et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 2003, 22:2361.
20. Li M., Wang I.X., Li Y., et al. Widespread RNA and DNA sequence differences in the human transcriptome. Science 2011, 333:53.
21. Ideker T., Thorsson V., Ranish J.A., et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001, 292:929.
22. Tian Q., Stepaniants S.B., Mao M., et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 2004, 3:960.
23. Macek B., Mann M., Olsen J.V. Global and site-specific quantitative phosphoproteomics: principles and applications. Annu Rev Pharmacol Toxicol 2009, 49:199.
24. Tan HT, Lee YH, Chung MC. Cancer proteomics. Mass Spectrom Rev 2012;31:583.
25. Mueller C., Liotta L.A., Espina V. Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol 2010, 4:461.
26. Malinowsky K., Wolff C., Ergin B., Berg D., Becker K.F. Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays. J Cell Physiol 2010, 225:364.
27. Wulfkuhle J.D., Speer R., Pierobon M., et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008, 7:1508.
28. Gembitsky D.S., Lawlor K., Jacovina A., Yaneva M., Tempst P. A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation. Mol Cell Proteomics 2004, 3:1102.
29. Nielsen U.B., Cardone M.H., Sinskey A.J., MacBeath G., Sorger P.K. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci U S A 2003, 100:9330.
30. Tibes R., Qiu Y., Lu Y., et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006, 5:2512.
31. Steelman L.S., Abrams S.L., Whelan J., et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008, 22:686.
32. Steelman L.S., Chappell W.H., Abrams S.L., et al. Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011, 3:192.
33. Cox D.M., Zhong F., Du M., Duchoslav E., Sakuma T., McDermott J.C. Multiple reaction monitoring as a method for identifying protein posttranslational modifications. J Biomol Tech 2005, 16:83.
34. Narumi R., Murakami T., Kuga T., et al. A strategy for large-scale phosphoproteomics and SRM-based validation of human breast cancer tissue samples. J Proteome Res 2012, 11:5311.
35. Domanski D., Murphy L.C., Borchers C.H. Assay development for the determination of phosphorylation stoichiometry using multiple reaction monitoring methods with and without phosphatase treatment: application to breast cancer signaling pathways. Anal Chem 2010, 82:5610.
36. Pan C., Olsen J.V., Daub H., Mann M. Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 2009, 8:2796.
37. Rubbi L., Titz B., Brown L., Galvan E., Komisopoulou E., Chen S.S. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci Signal 2011, 4:18.
38. Xue L., Wang W.H., Iliuk A., et al. Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase substrates. Proc Natl Acad Sci U S A 2012, 109:5615.
39. Andersen J.N., Sathyanarayanan S., Di Bacco A., et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2010, 2:43ra55.
40. Alcolea M.P., Casado P., Rodriguez-Prados J.C., Vanhaesebroeck B., Cutillas P.R. Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 2012, 11:453.
41. Iliuk A., Martinez J.S., Hall M.C., Tao W.A. Phosphorylation assay based on multifunctionalized soluble nanopolymer. Anal Chem 2011, 83:2767.
42. Iliuk A., Liu X.S., Xue L., Liu X., Tao W.A. Chemical visualization of phosphoproteomes on membrane. Mol Cell Proteomics 2012, 11:629.
43. Iliuk A.B., Martin V.A., Alicie B.M., Geahlen R.L., Tao W.A. In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion functionalized soluble nanopolymers. Mol Cell Proteomics 2010, 9:2162.
44. Mueller C., Edmiston K.H., Carpenter C., et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One 2011, 6:e23780.
45. Svensson M., Boren M., Skold K., et al. Heat stabilization of the tissue proteome: a new technology for improved proteomics. J Proteome Res 2009, 8:974.
46. Rountree C.B., Van Kirk C.A., You H., et al. Clinical application for the preservation of phospho-proteins through in-situ tissue stabilization. Proteome Sci 2010, 8:61.
47. Tian Q., Price N.D., Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med 2011, 271:111.
48. Chen R., Mias G.I., Li-Pook-Than J., et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012, 148:1293.